J Clin Med Res
Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc
Journal website http://www.jocmr.org

Original Article

Volume 11, Number 7, July 2019, pages 524-531


Clinical Manifestation and Incidence of Cardiopulmonary Complications in Early Systemic Sclerosis Patients with Different Antibody Profiles

Suparaporn Wangkaewa, d, Narawudt Prasertwittayakijb, Juntima Euathrongchitc

aDivision of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
bDivision of Cardiology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
cDivision of Diagnostic Radiology, Department of Radiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
dCorresponding Author: Suparaporn Wangkaew, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand

Manuscript submitted April 20, 2019, accepted May 13, 2019
Short title: Antibody Profile and Organ Complication in Early SSc
doi: https://doi.org/10.14740/jocmr3849

Abstract▴Top 

Background: There has been no prior inception cohort study comparing clinical manifestations and incidence rate (IR) of cardiopulmonary involvement among early systemic sclerosis (SSc) patients by difference in autoantibody profiles. We compared the differences in the clinical presentation at study entry and cumulative organ complications at last visit, as well as the IR of cardiopulmonary complications between anti-topoisomerase I antibody-positive SSc patients (pATA), ATA-negative (nATA), and the positive anti-centromere antibody patients (pACA).

Methods: An inception cohort of early diagnosis SSc patients (disease duration ≤ 3 years) seen at the Rheumatology Clinic, Maharaj Nakorn Chiang Mai Hospital, between January 2010 and June 2016, was studied. SSc patients who had follow-up duration as less than 1 year and those diagnosed with an overlap syndrome were excluded. All participants underwent electrocardiography (ECG), echocardiography, and high-resolution computed tomography (HRCT) at the study entry and then annually.

Results: A total of 114 patients (90 diffuse cutaneous SSc (dcSSc), 69 women) with mean (standard deviation, SD) disease duration of 11.7 (8.8) months at cohort entry and an observational period of 3.8 (1.6) years, were recruited. There were 89 patients (78.1%) with pATA, 18 (15.8%) with nATA, and 7 (6.1%) with pACA. At enrollment, both pATA and nATA groups had a higher prevalence of dcSSc subtype, and interstitial lung disease (ILD) when compared with the pACA group. At the last visit, the pATA group had a higher cumulative prevalence of digital ulcers, joint contracture and tendon friction rub than the other groups. Both the pATA and nATA groups had a significantly higher IR of ILD compared to the pACA group (54.9 and 57.8 vs. 6.3 per 100 person-years). During the study period, no suspected myositis, systolic pulmonary artery pressure (sPAP) ≥ 50 mm Hg or cardiac complications was observed in the pACA group.

Conclusions: In our study cohort, the majority of which were dcSSc subtype with pATA, it was found that the presence of SSc-specific autoantibodies was associated with a distinctive clinical presentation and cumulative internal organ involvement, even in the early phase of the disease. Cardiopulmonary complications were rarely seen in the pACA group; whereas ILD complications were very common in both the pATA and nATA groups. A further study into the association of autoantibodies in nATA patients with ILD complications is needed.

Keywords: Anti-topoisomerase I antibody; Anti-centromere antibody; Clinical manifestation; Incidence; Systemic sclerosis

Introduction▴Top 

Systemic sclerosis (SSc) is a complex autoimmune connective tissue disease of unknown etiology which is contributed by vascular injury, autoimmune alteration and fibrosis of the skin and visceral organs. SSc patients are mainly classified into diffuse cutaneous SSc (dcSSc) and limited cutaneous SSc (lcSSc) subsets according to the extent of skin involvement. Although dcSSc and lcSSc subsets are associated with organ manifestations, large cohort studies have shown that autoantibody status in SSc patients is also associated with clinical manifestations and organ system involvement as well as prognostic and survival features [1-4]. Information from both clinical subset and autoantibody status should be combined to evaluate the long-term prognosis of SSc patients [2].

Anti-topoisomerase I antibody (ATA) and anti-centromere antibody (ACA) are the autoantibodies routinely used in general clinical practice for early diagnosis of SSc according to the 2013 American College of Rheumatology (ACR)/the European League Against Rheumatism (EULAR) classification criteria for SSc [5]. Prior large prevalence studies have reported that there is a higher prevalence of the dcSSc subset [2, 3, 6-8], joint involvement [2, 3], tendon friction rub [2, 3], digital ulcers [2], interstitial lung disease (ILD) [2, 3, 6-8], pulmonary hypertension associated with ILD [2] and heart involvement [2, 3, 6, 7] in ATA-positive SSc patients than in the ACA-positive subset. On the other hand, there is a higher prevalence of the lcSSc subset [2, 3, 6] and isolated pulmonary hypertension [2, 3] in the ACA-positive patients. Therefore, the ATA-positive subset has been associated with more severe organ involvement [2, 3, 6-8] and poorer clinical outcome than the ACA-positive subset [1, 3].

Most reports which have pointed out comparisons between different autoantibody profiles regarding the prevalence of clinical manifestations have included SSc patients with variation in the phase of the course of the disease. Moreover, it has been reported that Thai SSc patients have a higher prevalence of an ATA-positive test (80-85.7%) [9, 10] than those from East Asia (Japan (23.5%) [7] and China (59.9%) [8]), and Western countries (22.2-36.8%) [3, 11]. Therefore, the difference seen in Thailand as regards the characteristics of autoantibody profiles may affect the clinical presentation and incidence of cardiopulmonary complications when compared to the earlier studies [3, 7, 8, 11].

In addition, there is no prior inception cohort study comparing clinical manifestations and incidence rate (IR) of cardiopulmonary involvement among SSc patients by difference in autoantibody profiles. Therefore, this inception cohort study was conducted to compare the differences in the initial clinical presentation and cumulative organ involvement, as well as the IR of cardiopulmonary complications between ATA-positive SSc patients, ATA-negative and ACA-positive SSc patients.

Materials and Methods▴Top 

Study population

This study cohort was recruited from the Rheumatology Clinic, Chiang Mai University, and included all consenting, consecutive adults (≥ 18 years). The cohort consisted of early diagnosed SSc patients (disease duration ≤ 3 years from first non-Raynaud’s phenomenon (NRP) attributable to SSc), from January 2010 to June 2016. All patients fulfilled the 1980 classification criteria of SSc [12] and/or the ACR/EULAR criteria 2013 for the classification of SSc [5]. The patients were classified as dcSSc or lcSSc in accordance with LeRoy and Medsger’s classification criteria [13]. Exclusion criteria were SSc patients who had follow-up duration from the enrolment on the study to their last visit as less than 1 year and those diagnosed with an overlap syndrome (SSc with systemic lupus erythematosus or SSc with rheumatoid arthritis).

Clinical evaluation

At cohort entry the following were recorded: demographic data, clinical presentation, and current medication. In addition laboratory tests were carried out including complete blood count, creatinine, creatine kinase (CK) levels, erythrocyte sedimentation rate (ESR), and prohormone of brain natriuretic peptide (proBNP) level. Tests for antinuclear antibodies and ACAs (by immunofluorescence on Hep2 cells), and ATA (by enzyme-linked immunosorbent assay (ELISA)) were also carried out. The severity of the skin involvement was assessed using a modified Rodnan skin score (mRSS) [14]. All participants underwent electrocardiography (ECG), echocardiography, and high-resolution computed tomography (HRCT) at the study entry and then annually. The ECG and echocardiography results were assessed by an experienced cardiologist (N. P.) blinded to the clinical data. The HRCT results were interpreted by an experienced thoracic radiologist (J. E.) blinded to the clinical data. The patients were seen at regular intervals between 1 and 3 months based on the severity of their disease and they received medical treatment as recommended by their attending rheumatologists.

Complete data, including clinical manifestations and blood tests, were collected every 6 months. At the last visit, the cumulative clinical manifestations were recorded. The survival status of the participants was recorded for all patients in June 2016.

Definitions

The onset of SSc was defined as the time of the first NRP attributable to SSc as reported by the patient. Duration of disease was calculated as the interval between the disease onset and the time at the study entry. Duration of follow-up was calculated as the interval between the cohort entry and the time of the last follow-up or death. Initial clinical characteristics were defined as the organ involvement detected at cohort entry. Cumulative clinical characteristic was defined as the presence of organ involvement being more than one in the recorded data during the observational period.

The presence of organ involvement was assessed as “yes” or “no” according to the following definitions: peripheral vascular manifestations were defined by the presence of Raynaud’s phenomenon (RP), digital pitting scar, digital ulcer or telangiectasia; a digital ulcer was defined as active or healed ulceration which was present at the volar aspect of the digital pulp.

Skin manifestation was defined by the presence of hypo-hyperpigmentation. Musculoskeletal manifestations were defined by the presence of arthritis, joint contracture, tendon friction rub, or suspected myositis. Joint contracture was defined as presence of stiffness in any joints, which decreased the range of motion and prevented full extension. Suspected myositis was defined as CK levels elevated to be ≥ 500 IU/L in the absence of other explainable causes such as statin use or hypothyroidism.

Gastrointestinal involvements were defined as the presence of gastroesophageal reflux disease (GERD) or dysphagia symptoms reported by the patient.

Cardiac involvements were defined by the presence of any of the following which were detected by echocardiography, in the absence of other explainable causes: 1) pericardial effusion; 2) left ventricular ejection fraction lower than 50% (LVEF < 50%); or 3) right ventricular dysfunction (RVD). RVD was defined as being present when the tricuspid annular plane systolic excursion (TAPSE) was less than 1.6 cm, the right ventricular annular velocity was less than 10 cm/s, the right ventricular fraction area change was less than 35%, or a localized right ventricular aneurysmal change was detected [15]. In addition, cardiac involvement was also defined as being existed if presence of conduction alteration was detected by ECG, which includes any bundle branch block, second or third degree atrioventricular block, QRS duration (QRSd) > 120 ms, or prolonged corrected QT (QTc) interval [16]. The prevalence of left ventricular diastolic dysfunction prior to 2016 was based on the 2009 recommendations for evaluation of left ventricular diastolic dysfunction by echocardiography [17]. Since 2016, the diagnosis is based on the 2016 recommendations for the evaluation of left ventricular diastolic function by echocardiography [18].

Pulmonary involvement was defined as the presence of: 1) ILD determined by HRCT, or 2) suspected pulmonary arterial hypertension defined as estimated systolic pulmonary arterial pressure (sPAP) being ≥ 50 mm Hg at rest, with normal LVEF determined by echocardiography [19].

Scleroderma renal crisis was defined as present if fulfilling the criteria described by the international scleroderma crisis study group [20].

Sicca symptoms were defined as present when ocular or oral dryness was reported by the patients.

Statistical analysis

The descriptive data are presented as percentages or mean ± SD, where appropriate. Clinical manifestations and laboratory investigations were compared between groups based on the three serological profiles (single ATA-positive (ATA-positive), both ATA and ACA-negative (ATA-negative) and single ACA-positive (ACA-positive)), using Chi-square test, Fisher’s exact test, one-way analysis of variance (ANOVA), and Kruskal-Wallis test as appropriate. The Mann-Whitney U test was used to compare nonparametric continuous variables between two subgroups. The time from first NRP to the first diagnosed LVEF < 50%, RVD, ILD and sPAP ≥ 50 mm Hg was analyzed using the Kaplan-Meier plot. The patient data were censored when: 1) any of the following cardiopulmonary involvements were detected: LVEF < 50%, RVD, ILD, or sPAP ≥ 50 mm Hg; and 2) any event occurred which included death or the end of the study was reached.

The comparison of the differences in cumulative incidence consisted of analysis of LVEF < 50%, RVD, ILD, and sPAP ≥ 50 mm Hg between the three serology subgroups, using the log-rank test. The IR of any cardiopulmonary involvement between the two groups was compared using the Mantel Haenszel method. P values < 0.05 were considered statistically significant. Statistical analyses were performed using Stata for Windows version 13.0 (StataCorp, College Station, TX, USA).

Ethics statement

This study was approved by the Chiang Mai University Research Ethics Committee in compliance with the 1964 Declaration of Helsinki and its later amendment. All patients gave written consent at study entry.

Results▴Top 

Demographic and clinical characteristics

Out of the 115 early-SSc patients which fulfilled the inclusion criteria and were initially enrolled into the study, one patient with dcSSc was excluded due to having a combined ATA-positive and ACA-positive test, leaving a cohort of 114 patients (69 women, 90 dcSSc) in the final analysis. Of the 114, there were 89 patients (78.1%) who were ATA-positive, 18 (15.8%) ATA-negative and seven (6.1%) ACA-positive. One hundred twelve patients (98.2%) had an ANA-positive result (titer ≥ 1:160), of which 71 (63.4%) had positive patterns as fine speckle and nucleolar, 13 (11.6%) coarse speckle, eight (7.1%) fine speckle, eight (7.1%) homogeneous, seven (6.3%) centromere, three (2.7%) homogeneous and nucleolar and two (1.7%) nucleolar. The mean ± SD age at disease onset was 51.4 ± 8.5 years and the duration of the disease from the first NRP to the study entry was 11.7 ± 8.8 months. The mean ± SD duration of follow-up from the study entry was 3.8 ± 1.6 years.

Demographic data between the three serology subgroupings at cohort entry were compared. The results are shown in Table 1. The ATA-positive group had a significantly higher prevalence dcSSc subtype compared to patients in the ATA-negative and ACA-positive groups. The ACA-positive subgroup had significantly longer mean disease duration from NRP to study entry compared to the ATA-positive and ATA-negative groups.

Table 1.
Click to view
Table 1. Demographics
 

There were no significant differences between the three serology subgroups with regard to age at disease onset, and duration of follow-up, as well as the proportion of presenting manifestation, and immunosuppressant or corticosteroid use. The mean ± SD dose of prednisolone was 3.0 ± 4.1 mg/day. At the end of the study, 87 patients (76.3%) continued follow-up, 13 (11.4%) referred themselves to other hospitals due to clinical improvement, eight (7.0%) failed to follow-up, and six (5.3%) patients died.

Comparison of clinical manifestations between serology subgroupings at cohort entry

At cohort entry, the ACA-positive group had a significantly higher prevalence of telangiectasia than the ATA-positive and ATA-negative groups. The ATA-positive group had a significantly higher prevalence of skin hypo-hyperpigmentation than the ATA-negative and ACA-positive groups. Both ATA-positive and ATA-negative groups showed a significantly higher prevalence of ILD compared to the ACA-positive group (80.9% and 77.8% vs. 0) (Table 2). Analysis of the initial laboratory tests showed that there were no significant differences between the three subgroupings (ATA-positive, ATA-negative and ACA-positive) with regard to values of creatinine, CK and proBNP.

Table 2.
Click to view
Table 2. Comparison of Initial Clinical Manifestations by Immunological Profile at Cohort Entry
 

According to the initial echocardiography, there were no significant differences between the three groups regarding the mean ± SD values of %LVEF (68.4 ± 7.9 vs. 66.7 ± 7.2 vs. 70.2 ± 4.5, P = 0.562), tricuspid regurgitation velocity (m/s) (2.4 ± 0.3 vs.2.6 ± 0.5 vs. 2.5 ± 0.3, P = 0.143), deceleration time (s) (0.22 ± 0.05 vs.0.21 ± 0.05 vs.0.19 ± 0.03, P = 0.184), and sPAP (31.6 ± 8.8 vs.36.5 ± 15.5 vs. 33.1 ± 6.1, P = 0.230). In addition, the prevalence of left ventricular diastolic dysfunction was comparable between the three groups (50.6% vs. 38.9% vs. 42.9%, P = 0.690).

Comparison of cumulative clinical manifestations between serology subgroupings at the last visit

At the last visit, the ATA-positive group had a higher cumulative clinical prevalence consisting of digital pitting scars, digital ulcers, telangiectasia, skin hypo-hyperpigmentation, joint contracture, and tendon friction rub than either the ATA-negative or ACA-positive group. In addition, both ATA-positive and ATA-negative groups had a higher cumulative proportion of ILD complications than the ACA-positive group (Table 3).

Table 3.
Click to view
Table 3. Comparison of Cumulative Clinical Manifestations by Immunological Profile at the Last Visit
 

Incidence of cardiopulmonary involvements

After the cohort entry, with a mean observational period of 4 years, 14 patients (12.3%) developed LVEF < 50%, 16 (14.0%) developed RVD, 10 (8.8%) developed ILD, five (4.4%) developed sPAP ≥ 50 mm Hg, and six died (5.3%).

Over the observational time from NRP, there were no significant differences between the three groups with regard to the cumulative incidence of LVEF < 50% (P = 0.271) (Fig. 1a), RVD (P = 0.200) (Fig. 1b) and sPAP ≥ 50 mm Hg (P = 0.223) (Fig. 1c). Interestingly, both the ATA-positive and ATA-negative groups showed significantly higher cumulative incidence of ILD compared to the ACA-positive group (P = 0.006) (Fig. 1d). There were no cardiopulmonary complications including LVEF < 50%, RVD and sPAP ≥ 50 mm Hg observed in the ACA-positive group.

Figure 1.
Click for large image
Figure 1. The cumulative incidence of (a) LVEF < 50%, (b) RV dysfunction, (c) suspected PH, and (d) ILD in early SSc patients by different antibody profiles. The P value was from the log-rank test. LVEF: left ventricular ejection fraction; RV: right ventricular; PH: pulmonary arterial hypertension; ILD: interstitial lung disease.

The IR of ILD complications per 100 person-years belonging to the ATA-positive, ATA-negative, and ACA-positive groups were 54.99, 57.83 and 6.33, respectively. The IR ratio of ILD complications between ATA-positive and ACA-positive groups was 8.68 (95% confidence interval (CI) 2.32 - 72.98). In addition, the IR ratio of ILD complications between the ATA-negative and ACA-positive groups was 9.13 (95% CI 2.15 - 81.87).

There was comparable modest IR between the ATA-positive and ATA-negative groups according to LVEF < 50% (3.83 per 100 person-years vs. 1.36 per 100 person-years, P = 0.319), RVD (4.80 per 100 person-years vs. 1.40 per 100 person-years, P = 0.202), and sPAP ≥ 50 mm Hg (1.86 per 100 person-years vs. 4.60 per 100 person-years, P = 0.223).

Discussion▴Top 

To our knowledge, this is an inception cohort study in SSc patients in early stages of the disease (disease duration ≤ 3 years) describing the association of clinical manifestations and IR of cardiopulmonary based on different autoantibody profiles routinely used in general practice. Our cohort included a homogeneous study population of SSc patients in early phases of the disease with a mean disease duration of 1 year from the first NRP to study entry.

This study population had a high prevalence in the dcSSc subset (78.9%) and ATA-positive patients (78.1%) which were higher than the 22.2-36.8% range of ATA-positive patients reported by Western countries [3, 11], which should be highlighted. In addition in our study population, there was a low prevalence of ACA-positive patients (6.1%) which is lower than the range of 20.3-32.3% reported by Western studies [3, 11]. Our study found that ATA-positive patients had a higher prevalence of the dcSSc subset (88.8%) and had shorter disease duration from the first NRP to study entry, suggesting a rapidly progressive disease course compared to ACA-positive patients concordant with other studies [2-4].

At study entry, we found that ATA-positive patients had more severe mRSS and a higher proportion of hypo-hyperpigmentation, but had a lower proportion of telangiectasia than ACA-positive patients. In addition, ATA-negative SSc patients, of whom half were in the dcSSc subset, tended to have less severe clinical manifestations with respect to mRSS, telangiectasia and hypo-hyperpigmentation compared to ATA-positive patients.

Interestingly, both ATA-positive and ATA-negative patients had a high comparable prevalence of ILD, whereas no ILD was observed in ACA-positive patients, suggesting both ATA-positive and ATA-negative SSc patients had more severe ILD complications than the ACA-positive patients. The non-specific interstitial pneumonitis (NSIP) pattern was the most common HRCT finding in both ATA-positive (69.7%) and ATA-negative subsets (72.7%).

At the last visit, at the end of the mean observational period of 3.8 years, there were some differences in organ complications in the ATA-positive group. These consisted of a significantly higher cumulative prevalence of digital pitting scars, digital ulcers, telangiectasia, skin hypo-hyperpigmentation, joint contracture, tendon friction rub and ILD, suggesting more severe organ involvement and a more rapid progress of the disease even in the early phases, compared to the ATA-negative and ACA-positive groups. Similarly, data from other large studies supports the findings that ATA-positive patients had more severe cumulative organ complications than ACA-positive patients [2-4, 6].

As regards cumulative prevalence of internal organ involvement, no significant differences were observed in the three serologic profile-related gastrointestinal, cardiac, and sicca symptoms, with findings concordant with Iniesta Arandia et al’s report [4]. Contrary to this, Walker et al reported that cardiac involvement consisting of conduction block and diastolic dysfunction was more prevalent in an ATA-positive group than in an ACA-positive group [2]. The discrepancies regarding the prevalence of organ involvement based on the different serologic profiles might be attributable to differences in study population, definition of organ involvement, and follow-up duration. Our study included patients in the early phase of SSc with short duration of follow-up which differed from a prior study [2].

There was no suspected myositis or cardiac complications observed in ACA-positive SSc patients during the observational period. However, there was a significantly higher IR of ILD complications in both the ATA-positive and ATA-negative groups when compared to the ACA-positive group. Our study found modest IRs of %LVEF < 50%, RVD, and sPAP ≥ 50 mm Hg which were similar among the three autoantibody profiles. To our knowledge, data regarding the IR of these cardiopulmonary complications in early phase of SSc comparing between different antibody profiles is limited.

The major limitations of this study include the small sample size of early-SSc patients with a positive test for ACA. In addition, further SSc-specific autoantibody testing for 18 ATA-negative SSc patients was not available during the study period. As the observational period was of short duration, with a mean observational period of 4 years from the study entry, our findings should be interpreted with caution. In addition we did not include early immunosuppressive treatment in our analysis due to the potential bias in the observational study. Another major limitation is that patients with suspected pulmonary arterial hypertension were not confirmed by right heart catheterization.

The strength of this study is that it is the first inception cohort study in early-SSc patients (disease duration ≤ 3 years) to determine the difference in the clinical manifestations and IR of cardiopulmonary complications in a comparison based on routinely used autoantibody profiles in general clinical practice. An additional strength is that it is a single-center assessment with a limited number of investigators and uniform clinical, echocardiography, and HRCT assessments giving a consistency to the data collection and management.

Conclusions

In our study cohort, with majority of the patients being early dcSSc subtype who were ATA-positive, it was found that the presence of ATA or ACA is associated with distinctive presenting and cumulative organ involvement even in the early phase of disease in SSc patients. Cardiopulmonary complications were rarely seen in the ACA-positive group, whereas ILD complications were very common in both the ATA-positive and ATA-negative groups. A further study into the association of specific autoantibodies in ATA-negative patients with ILD complications is needed.

Acknowledgments

We would like to thank Mrs. Antika Wongthanee, medical statistician, for help with the statistical analysis.

Financial Disclosure

Authors have no financial disclosure to report.

Conflict of Interest

The authors declare that they have no conflict of interest concerning this article.

Informed Consent

All patients gave written consent at study entry.

Author Contributions

SW designed the research; SW, NP and JE collected data; SW and AW analyzed data; SW wrote the paper. All authors read and approved the final paper.


References▴Top 
  1. Hesselstrand R, Scheja A, Shen GQ, Wiik A, Akesson A. The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis. Rheumatology (Oxford). 2003;42(4):534-540.
    doi pubmed
  2. Walker UA, Tyndall A, Czirjak L, Denton C, Farge-Bancel D, Kowal-Bielecka O, Muller-Ladner U, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis. 2007;66(6):754-763.
    doi pubmed
  3. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum. 2005;35(1):35-42.
    doi pubmed
  4. Arandia NI, Simeon-Aznar CP, del Castillo AG, Arguelles DC, Rubio-Rivas M, Martinez LT, Hernandez FJG, et al. Influence of antibody profile in clinical features and prognosis in a cohort of Spanish patients with systemic sclerosis. Clin Exp Rheumatol. 2017;35 Suppl 106(4):98-105.
  5. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11):1747-1755.
    doi pubmed
  6. Denton CP, Krieg T, Guillevin L, Schwierin B, Rosenberg D, Silkey M, Zultak M, et al. Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO Registry. Ann Rheum Dis. 2012;71(5):718-721.
    doi pubmed
  7. Hashimoto A, Endo H, Kondo H, Hirohata S. Clinical features of 405 Japanese patients with systemic sclerosis. Mod Rheumatol. 2012;22(2):272-279.
    doi pubmed
  8. Wang J, Assassi S, Guo G, Tu W, Wu W, Yang L, Xiao R, et al. Clinical and serological features of systemic sclerosis in a Chinese cohort. Clin Rheumatol. 2013;32(5):617-621.
    doi pubmed
  9. Foocharoen C, Suwannachat P, Netwijitpan S, Mahakkanukrauh A, Suwannaroj S, Nanagara R, Scleroderma Research G. Clinical differences between Thai systemic sclerosis patients with positive versus negative anti-topoisomerase I. Int J Rheum Dis. 2016;19(3):312-320.
    doi pubmed
  10. Wangkaew S, Prasertwitayakij N, Phrommintikul A, Puntana S, Euathrongchit J. Causes of death, survival and risk factors of mortality in Thai patients with early systemic sclerosis: inception cohort study. Rheumatol Int. 2017;37(12):2087-2094.
    doi pubmed
  11. Meier FM, Frommer KW, Dinser R, Walker UA, Czirjak L, Denton CP, Allanore Y, et al. Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis. 2012;71(8):1355-1360.
    doi pubmed
  12. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980;23(5):581-590.
    doi
  13. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, Jr., Rowell N, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15(2):202-205.
  14. Clements P, Lachenbruch P, Siebold J, White B, Weiner S, Martin R, Weinstein A, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol. 1995;22(7):1281-1285.
  15. Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, Solomon SD, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr. 2010;23(7):685-713; quiz 786-688.
    doi pubmed
  16. Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, Philippides GJ, et al. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation. 2010;121(8):1047-1060.
    doi pubmed
  17. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr. 2009;22(2):107-133.
    doi pubmed
  18. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, 3rd, Dokainish H, Edvardsen T, Flachskampf FA, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29(4):277-314.
    doi pubmed
  19. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2009;34(6):1219-1263.
    doi pubmed
  20. Hudson M, Baron M, Tatibouet S, Furst DE, Khanna D, International Scleroderma Renal Crisis Study I. Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-results from the International Scleroderma Renal Crisis Survey. Semin Arthritis Rheum. 2014;43(5):666-672.
    doi pubmed


This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.


Journal of Clinical Medicine Research is published by Elmer Press Inc.

 

Browse  Journals  

 

Journal of Clinical Medicine Research

Journal of Endocrinology and Metabolism

Journal of Clinical Gynecology and Obstetrics

 

World Journal of Oncology

Gastroenterology Research

Journal of Hematology

 

Journal of Medical Cases

Journal of Current Surgery

Clinical Infection and Immunity

 

Cardiology Research

World Journal of Nephrology and Urology

Cellular and Molecular Medicine Research

 

Journal of Neurology Research

International Journal of Clinical Pediatrics

 

 
       
 

Journal of Clinical Medicine Research, monthly, ISSN 1918-3003 (print), 1918-3011 (online), published by Elmer Press Inc.                     
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)


This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website: www.jocmr.org   editorial contact: editor@jocmr.org     elmer.editorial2@hotmail.com
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.


Disclaimer: The views and opinions expressed in the published articles are those of the authors and do not necessarily reflect the views or opinions of the editors and Elmer Press Inc. This website is provided for medical research and informational purposes only and does not constitute any medical advice or professional services. The information provided in this journal should not be used for diagnosis and treatment, those seeking medical advice should always consult with a licensed physician.